Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Feb 17;12(2):e0172348.
doi: 10.1371/journal.pone.0172348. eCollection 2017.

Elevated GM3 plasma concentration in idiopathic Parkinson's disease: A lipidomic analysis

Affiliations

Elevated GM3 plasma concentration in idiopathic Parkinson's disease: A lipidomic analysis

Robin B Chan et al. PLoS One. .

Abstract

Parkinson's disease (PD) is a common neurodegenerative disease whose pathological hallmark is the accumulation of intracellular α-synuclein aggregates in Lewy bodies. Lipid metabolism dysregulation may play a significant role in PD pathogenesis; however, large plasma lipidomic studies in PD are lacking. In the current study, we analyzed the lipidomic profile of plasma obtained from 150 idiopathic PD patients and 100 controls, taken from the 'Spot' study at Columbia University Medical Center in New York. Our mass spectrometry based analytical panel consisted of 520 lipid species from 39 lipid subclasses including all major classes of glycerophospholipids, sphingolipids, glycerolipids and sterols. Each lipid species was analyzed using a logistic regression model. The plasma concentrations of two lipid subclasses, triglycerides and monosialodihexosylganglioside (GM3), were different between PD and control participants. GM3 ganglioside concentration had the most significant difference between PD and controls (1.531±0.037 pmol/μl versus 1.337±0.040 pmol/μl respectively; p-value = 5.96E-04; q-value = 0.048; when normalized to total lipid: p-value = 2.890E-05; q-value = 2.933E-03). Next, we used a collection of 20 GM3 and glucosylceramide (GlcCer) species concentrations normalized to total lipid to perform a ROC curve analysis, and found that these lipids compare favorably with biomarkers reported in previous studies (AUC = 0.742 for males, AUC = 0.644 for females). Our results suggest that higher plasma GM3 levels are associated with PD. GM3 lies in the same glycosphingolipid metabolic pathway as GlcCer, a substrate of the enzyme glucocerebrosidase, which has been associated with PD. These findings are consistent with previous reports implicating lower glucocerebrosidase activity with PD risk.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: None of the authors have any disclosures relating to the content of this manuscript. Robin B. Chan, Adler J. Perotte, Bowen Zhou, Christopher Liong, Evan J. Shorr, Un J. Kang, Oren A. Levy, Yimeng Xu, Hong Bin Shim and Itsik Pe’er have nothing to disclose. Cheryl Waters reports receiving consultation fees from Prophase, Lundbek, Impax and Acorda. Karen Marder reports grants from NIH [NS036630 (PI), 1UL1 RR024156-01 (Director PCIR), PO412196- G (Co-I), and PO412196-G (Co-I)], grants from steering committee for U01NS052592, grants from the Parkinson’s Disease Foundation, and grants from Michael J Fox Foundation, outside the submitted work. Gilbert Di Paolo is currently an employee of Denali Therapeutics Inc., and Roy N. Alcalay reports receiving consultation fees from Prophase and Genzyme/Sanofi, and grants from the Michael J Fox Foundation, the Parkinson’s Disease Foundation and the NIH (K02NS080915).

Figures

Fig 1
Fig 1. Higher levels of GM3 in PD patients compared to controls.
Scatter plots are shown for total GM3 (A), and for the GM3 species GM3 d18:1/24:1 (B) and GM3 d18:1/26:0 (C).
Fig 2
Fig 2. GM3 levels are more predictive of male PD status.
The receiver operating characteristic (ROC) curves for male (A) and female (B) participants in our studies are shown. Their respective AUC is shown with the graph.

References

    1. Di Paolo G, Kim TW (2011) Linking lipids to Alzheimer's disease: cholesterol and beyond. Nature Reviews Neuroscience 12: 284–296. 10.1038/nrn3012 - DOI - PMC - PubMed
    1. Block RC, Dorsey ER, Beck CA, Brenna JT, Shoulson I (2010) Altered cholesterol and fatty acid metabolism in Huntington disease. J Clin Lipidol 4: 17–23. 10.1016/j.jacl.2009.11.003 - DOI - PMC - PubMed
    1. Ruiperez V, Darios F, Davletov B (2010) Alpha-synuclein, lipids and Parkinson's disease. Prog Lipid Res 49: 420–428. 10.1016/j.plipres.2010.05.004 - DOI - PubMed
    1. Mattson MP (2004) Metal-catalyzed disruption of membrane protein and lipid signaling in the pathogenesis of neurodegenerative disorders. Ann N Y Acad Sci 1012: 37–50. - PubMed
    1. Iyer A, Petersen NO, Claessens MM, Subramaniam V (2014) Amyloids of alpha-synuclein affect the structure and dynamics of supported lipid bilayers. Biophys J 106: 2585–2594. 10.1016/j.bpj.2014.05.001 - DOI - PMC - PubMed